Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1996-1-19
|
| pubmed:abstractText |
It is apparent that multiple end points are required to adequately describe the response to therapy for CTCL. Investigators may differ as to which end points are best suited for their data. In general, multiple end points provide a better overall view of response to treatment as compared with a single end point. Regardless, measures of response and end points should be clearly defined and the methods of calculating end points clearly stated.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0889-8588
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1021-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8522482-Humans,
pubmed-meshheading:8522482-Lymphoma, T-Cell, Cutaneous,
pubmed-meshheading:8522482-Neoplasm Staging,
pubmed-meshheading:8522482-Quality of Life,
pubmed-meshheading:8522482-Randomized Controlled Trials as Topic,
pubmed-meshheading:8522482-Skin Neoplasms,
pubmed-meshheading:8522482-Survival Rate,
pubmed-meshheading:8522482-Treatment Outcome
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Assessing clinical outcomes in cutaneous T-cell lymphoma.
|
| pubmed:affiliation |
University of California at San Francisco, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Review
|